CClinicalTrials.gg
Not yet recruitingNCT06669923SSB and CRCUpdated Nov 1, 2024

Understanding Sugar-Sweetened Beverages (SSB) and Colorectal Cancer (CRC)

An interventional study of iSIPsmarter Program and Patient Education in Colorectal Neoplasms, sponsored by University of Virginia. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by University of Virginia · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will recruit and consent approximately 120 subjects in the baseline study until the follow-up study recruitment goals of 20 subjects is met. This pilot proposal to: Aim 1) assess the feasibility of conducting a randomized controlled trial of iSIPsmarter among high-risk patients with newly detected large colorectal adenoma to reduce Sugar-Sweetened Beverages (SSB) consumption, and Aim 2) examine the investigators' central hypothesis that SSBs contribute to racial disparities in the development of side-specific colon neoplasia via differentially impacting epigenetic aging and methylation of right vs. left normal colon tissues of African-Americans (AA) vs European-Americans (EA). In order to do so, the investigators will first conduct a study to collect baseline information from eligible and interested participants. Behavioral, lifestyle, and genetic information will be collected from participants undergoing a colonoscopy with large polypectomy removal to set up a biobank. The participants enrolled in this study will then be screened for their interest and eligibility in participating in the follow-up study, a randomized iSIPsmarter intervention trial. The investigators will enroll 20 patients in the follow-up study (1:1 ratio intervention vs. control; equal number of AAs and EAs) with newly detected/resected large colorectal adenomas to collect normal colon tissue biopsies pre- and post-iSIPsmarter intervention and test the investigators' hypotheses.

02

Conditions studied

  • Colorectal Neoplasms
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's planned enrollment of 120 is above the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

University of Virginia is the lead sponsor of 653 studies on the registry; 134 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 41 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Baseline Study:

Inclusion Criteria:

  • Patients scheduled for a colonoscopy (large polyp removal)
  • Patients 18+

Exclusion Criteria:

  • Subjects who do not speak English
  • Subjects diagnosed with inflammatory bowel disorder
  • Subjects diagnosed with cancer (except non-melanoma skin cancer)
  • Subjects taking blood thinners at time of colonoscopy (except 325 mg daily aspirin)

Follow-up Study:

In order to be eligible to participate in the f/up study, an individual must meet all of the criteria for the Baseline study AND:

Inclusion Criteria:

  • Regular access (\<1/week) to the internet.
  • Drink more than recommended amount of sugar-sweetened beverages per day (assessed from participant's responses to the Beverage Questionnaire section (BEVQ-15) of the Computer Administered Phone Interview (CAPI), from the Baseline study).
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • No intervention
    Baseline

    Baseline study collects baseline data and screens for potential participants for the follow-up study.

  • Sham comparator
    Follow Up - Patient Education Group

    Behavioral: Patient Education

  • Experimental
    Follow Up - iSIPsmarter Program Group

    Behavioral: iSIPsmarter Program

Interventions

  • BehavioraliSIPsmarter Program

    web-based behavioral intervention to reduce sugary drink intake

    Also known as: Sugary Drink Program

  • BehavioralPatient Education

    website with information about cancer screening and prevention (e.g. screening tests for seven types of cancer)

    Also known as: Cancer Prevention Program

06

What researchers measure

Primary outcomes

  1. Change from baseline sugar-sweetened beverages

    Measured using the Beverage Questionnaire 15 (BEVQ-15), measured in oz

    Time frame: Baseline, 9-weeks, 6-months, 18 months

Secondary outcomes

  1. Degree of physiological aging, assessed by DNA methylation, of right vs. left colorectal tissue biopsies at Baseline and 6 months.

    Measured by comparing baseline physiological aging of right vs. left colon tissue biopsies with biopsies collected 6 months post-intervention.

    Time frame: Baseline, 6 months

  2. Degree of physiological aging, assessed by DNA methylation, of right vs. left colorectal tissue biopsies at Baseline and 18 months.

    Measured by comparing baseline physiological aging of right vs. left colon tissue biopsies with biopsies collected 18 months post-intervention.

    Time frame: Baseline, 18 months

  3. Change from baseline dietary quality as measured by the components of the Healthy Eating Index (HEI)

    2 unannounced recalls (one weekend and one weekday) using state-of-the-art Nutrition Data System for Research (NDSR) software and multiple pass methods. HEI indicators will be extracted from the NDSR system and examined for changes in the total HEI score, on a 100-point continuous scale (higher scores reflective higher diet quality)

    Time frame: Baseline, 9-weeks, 6-months, 18 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06669923
Lead sponsor
University of Virginia
Responsible party
Li Li (Principal Investigator, University of Virginia) — Principal investigator
First posted
Nov 1, 2024
Start date
Nov 15, 2024 (estimated)
Primary completion
Nov 15, 2029 (estimated)
Completion
Nov 15, 2030 (estimated)
Last update
Nov 1, 2024

Study contacts

Samyukta Venkatesh, BA
Contact
qgf7up@uvahealth.org
4342434983
Donna-Jean Brock, MA
Contact
djbrock@virginia.edu
434-962-5870
Li Li, MD, PhD
principal investigator · UVA, Dept of Family Medicine
Jamie Zoellner, PhD, RD
principal investigator · UVA, Dept of Public Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion